Hinova Pharmaceuticals Inc. (SHA:688302)
China
· Delayed Price · Currency is CNY 42.03
-0.57 (-1.34%)
Mar 9, 2026, 4:00 PM EDT
Hinova Pharmaceuticals Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Cash & Equivalents | - | 633.44 | 813.23 | 1,202 | 901.22 | Upgrade
|
| Trading Asset Securities | - | 210.49 | 290.62 | 366.24 | - | Upgrade
|
| Cash & Short-Term Investments | 917.05 | 843.93 | 1,104 | 1,568 | 901.22 | Upgrade
|
| Cash Growth | 8.66% | -23.55% | -29.59% | 73.97% | -20.85% | Upgrade
|
| Other Receivables | - | 0.84 | 1.39 | 1.67 | 0.54 | Upgrade
|
| Receivables | - | 0.84 | 1.39 | 1.67 | 0.54 | Upgrade
|
| Inventory | - | 0 | 0.01 | 0.01 | 0 | Upgrade
|
| Prepaid Expenses | - | - | - | - | 13.09 | Upgrade
|
| Other Current Assets | - | 40.77 | 41.99 | 41.78 | 40.38 | Upgrade
|
| Total Current Assets | - | 885.54 | 1,147 | 1,611 | 955.24 | Upgrade
|
| Property, Plant & Equipment | - | 328.62 | 187.99 | 86.61 | 12.72 | Upgrade
|
| Long-Term Investments | - | 113.09 | 109.98 | 5 | - | Upgrade
|
| Other Intangible Assets | - | 30.56 | 31.21 | 31.86 | - | Upgrade
|
| Long-Term Deferred Charges | - | - | 0.04 | 0.08 | - | Upgrade
|
| Other Long-Term Assets | - | 3.77 | 15.12 | 0.21 | 14.39 | Upgrade
|
| Total Assets | - | 1,362 | 1,492 | 1,735 | 982.35 | Upgrade
|
| Accounts Payable | - | 40.63 | 3.14 | 2.29 | 1.31 | Upgrade
|
| Accrued Expenses | - | 31.09 | 49.17 | 69.81 | 90.45 | Upgrade
|
| Short-Term Debt | - | - | - | 30 | - | Upgrade
|
| Current Portion of Leases | - | 3.22 | 3.77 | 2.45 | 2.8 | Upgrade
|
| Other Current Liabilities | - | 72.01 | 50.76 | 33.73 | 96.77 | Upgrade
|
| Total Current Liabilities | - | 146.95 | 106.84 | 138.27 | 191.33 | Upgrade
|
| Long-Term Leases | - | 5.83 | 9.08 | 3.31 | 1.11 | Upgrade
|
| Long-Term Unearned Revenue | - | 16.55 | 8.55 | 8.1 | 1.15 | Upgrade
|
| Total Liabilities | - | 169.33 | 124.47 | 149.68 | 193.59 | Upgrade
|
| Common Stock | - | 99.02 | 99.02 | 99.02 | 74.26 | Upgrade
|
| Additional Paid-In Capital | - | 2,583 | 2,558 | 2,482 | 1,409 | Upgrade
|
| Retained Earnings | - | -1,490 | -1,290 | -996.06 | -694.54 | Upgrade
|
| Comprehensive Income & Other | - | -0.03 | 0.11 | 0.14 | -0.07 | Upgrade
|
| Total Common Equity | 1,101 | 1,192 | 1,367 | 1,585 | 788.76 | Upgrade
|
| Shareholders' Equity | 1,101 | 1,192 | 1,367 | 1,585 | 788.76 | Upgrade
|
| Total Liabilities & Equity | - | 1,362 | 1,492 | 1,735 | 982.35 | Upgrade
|
| Total Debt | 106.67 | 9.05 | 12.85 | 35.76 | 3.91 | Upgrade
|
| Net Cash (Debt) | 810.38 | 834.88 | 1,091 | 1,532 | 897.31 | Upgrade
|
| Net Cash Growth | -2.94% | -23.48% | -28.79% | 70.74% | -21.16% | Upgrade
|
| Net Cash Per Share | 8.18 | 8.41 | 11.02 | 16.87 | 12.07 | Upgrade
|
| Filing Date Shares Outstanding | 98.75 | 99.02 | 99.02 | 99.02 | 74.26 | Upgrade
|
| Total Common Shares Outstanding | 99.02 | 99.02 | 99.02 | 99.02 | 74.26 | Upgrade
|
| Working Capital | - | 738.59 | 1,040 | 1,473 | 763.91 | Upgrade
|
| Book Value Per Share | 11.12 | 12.04 | 13.81 | 16.01 | 10.62 | Upgrade
|
| Tangible Book Value | 1,070 | 1,162 | 1,336 | 1,554 | 788.76 | Upgrade
|
| Tangible Book Value Per Share | 10.80 | 11.73 | 13.49 | 15.69 | 10.62 | Upgrade
|
| Machinery | - | 17.15 | 15.49 | 14.85 | 11.16 | Upgrade
|
| Construction In Progress | - | 314.5 | 169.54 | 73.76 | 3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.